BioCentury | Nov 8, 2018
Emerging Company Profile

Abarceo: restoring beta cell function

Abarceo Pharma AB has identified VDAC1 as a key target in Type II diabetes, and is developing antibodies and small molecule inhibitors against the target as durable and disease-modifying treatments. Standard first-line therapy for Type...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Neurology; ophthalmic disease

INDICATION: Parkinson’s disease (PD); neurology; blindness Fruit fly studies suggest inhibiting ITPR, VDAC1, MCU, MIRO1 and/or MIRO2 could help treat PD, other neurodegenerative diseases and blindness. In a Drosophila model of PD, knockdown of ITPR...
BioCentury | Nov 10, 2017
Clinical News

Vidac reports Phase IIa data for VDA-1102 in actinic keratosis

Vidac Pharma Ltd. (Jerusalem, Israel) said 10% VDA-1102 ointment missed the primary endpoint of reducing the mean number of actinic keratosis (AK) lesions on the face or scalp combined from baseline to day 56 vs....
BioCentury | Jun 1, 2017
Tools & Techniques

WuXi ex machina

Since its acquisition two years ago by New WuXi Life Science Ltd. , WuXi NextCode Genomics Inc. has been busy building out its artificial intelligence (AI) capabilities and test driving them via its expanding network of...
BioCentury | Jul 11, 2016
Finance

Advising Israel

BC Staff A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel Biotech Fund is raising its first...
BioCentury | Jul 1, 2016
Financial News

Vidac raises $9M series A round

Vidac Pharma (Jerusalem, Israel) raised $9 million in a series A financing led by new investor Israel Biotech Fund. Existing investors including Mivtach Shamir Holdings also participated. The company's VDA-1102 ointment is in a Phase...
BioCentury | Feb 25, 2016
Distillery Therapeutics

Therapeutics: Voltage-dependent anion channel 1 (VDAC1)

Neurology INDICATION: Diabetic neuropathy; neuropathy Mouse studies suggest inhibiting VDAC1 could help treat diabetic neuropathy and Charcot-Marie-Tooth 1A (CMT1A) disease. In mouse models of diabetic neuropathy and CMT1A, a VDAC1 inhibitor tool compound increased nerve...
Items per page:
1 - 7 of 7